Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Mosunetuzumab + Tocilizumab|
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Mosunetuzumab||RG7828|BTCT4465A|RO7030816|BTCT-4465A||CD20 Antibody 17||Mosunetuzumab (BTCT4465A) is a bispecific antibody targeting CD20 and CD3, which results in killing of CD20-positive tumor cells (PMID: 25972002, PMID: 29351372)|
|Tocilizumab||Actemra||Atlizumab||Actemra (tocilizumab) is a humamized monoclonal antibody that targets IL-6R, resulting in decreased downstream signaling and potentially resulted in decreased tumor growth and progression (PMID: 26751841, PMID: 25658637). Actemra (tocilizumab) is FDA approved for use in treating rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, and systemic juvenile idiopathic arthritis (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|
|NCT03677154||Phase Ib/II||Mosunetuzumab + Tocilizumab||A Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Therapy in Participants With Previously Untreated Diffuse Large B-Cell Lymphoma Who Are Unable to Tolerate Full-Dose Chemotherapy||Recruiting||USA | ESP||4|
|NCT05207670||Phase II||Mosunetuzumab + Tocilizumab||A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (MorningSun)||Recruiting||USA||0|
|NCT05091424||Phase I||Mosunetuzumab + Tocilizumab||A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia||Recruiting||USA | ITA | FRA | ESP | DEU||2|